GlobeNewswire Clinical StudiesOriginal article
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
Data ReadoutpositiveBBP-418Positive
AI Analysis
Summary
BBP-418 demonstrated disease-modifying potential in exploratory Month 12 analyses in LGMD2I/R9 patients, with 100% of treated patients achieving normal HS troponin I levels versus 40% on placebo, suggesting restoration of cardiac function markers.
Clinical Trial Data
Outcome Details
Month 12 exploratory analyses showed 100% of BBP-418 treated patients with elevated baseline HS troponin I returned to normal range versus 40% placebo (p=0.0248); HS troponin I declined more with BBP-418 than placebo (p=0.0443)
Importance:6/10
Sentiment:
0.75
cardiac marker improvementdisease-modifying potentialLGMD2Itroponin normalizationexploratory analysis
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on October 5, 2026 11:30 AM